AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03952572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750mg/m² ivgtt on day 1
Study NCT03952572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 750mg/m² ivgtt on day 1
Study NCT03952572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin
Description: 40mg/m² ivgtt on day 1
Study NCT03952572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4mg/m²(Maximum 2 mg) ivgtt on day 1
Study NCT03952572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: 1.4mg/m²(Maximum 2 mg) ivgtt on day 1
Study NCT03952572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone100mg/m² po on day1-5
Study NCT03952572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone100mg/m² po on day1-5
Study NCT03952572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 50mg/m² ivgtt on day 1
Study NCT04572776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resiniferatoxin
Description: Resiniferatoxin is a TRPV-1 agonist which works by specifically ablating nociceptive nerve fibers.
Study NCT04572776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care for intractable pain with the exception of intra-thecal pump placement as determined by the investigator.
Study NCT03783377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-APOC3
Description: single or multiple doses of ARO-APOC3 by subcutaneous (sc) injections
Study NCT03783377 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sterile normal saline (0.9% NaCl)
Description: calculated volume to match active treatment
Study NCT03202290 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive and clinical assessment
Description: The content of the assessment will be the same for all subjects and will consist of a cognitive assessment (neurocognition, social cognition, metacognition, emotional reactivity) and a clinical assessment (impulsivity, personality, psychriatric and addictive comorbidities)
Study NCT03762577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ground-based walking training
Description: Patients will attend a 2-day 30-minute ground-based walking training under the supervision of a physiotherapist. Patients will walk for 1-2 days in a week without supervision. According to the Modified Borg Scale, the dyspnea intensity will be 3-4 (medium to slightly difficult) and the heart rate will be completed to not exceed 120 min / pulse. Heart rate of patients will be followed by finger type pulse oximeter
Study NCT04265222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hipcheck Software
Description: Software
Study NCT04265222 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Fluoroscopy
Description: Conventional Fluoroscopy
Study NCT04147247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 905681
Description: Infusion
Study NCT03362177 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: This study is designed to study Romiplostim for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for the treatment of gastrointestinal/colorectal/pancreatic cancer.
Study NCT03362177 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study NCT05409950 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate implant placement using socket shield technique
Description: Evaluation of socket shield technique with immediate implant placement at the esthetic zone in comparison with the conventional immediate implant placement
Study NCT03592836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loop Diuretics
Description: intravenous administration of diuretics
Study NCT03407001 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast-Enhanced Ultrasound
Description: Undergo CEUS
Study NCT03407001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfur Hexafluoride Lipid Microspheres
Description: Given IV
Study NCT03407001 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Undergo non-contrast US
Study NCT00789607 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transrectal APT Device or Transperineal Device will be used
Description: Both are imaging probe devices that is inserted under local anesthetic, in the rectum using lubricant, positioning against the prostate gland, and attached to the table. This is done at baseline (Day 0) under local anesthetic with the patient in partial dorsal lithotomy position
Study NCT00789607 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TRUS probe
Description: Patient is given local anesthetic transrectally to the prostate base and the probe is inserted with patient in the lateral decubitus position.
Study NCT00206427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW572016
Description: Lapatinib, 500 mg
Study NCT00206427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: Lapatinib 500 mg PO
Study NCT03877146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Controlled Breathing Intervention
Description: Participants in the controlled breathing intervention will be provided with headphones to listen to the guided intervention audio file. The intervention will guide participants to breathe at a rate of six breaths per minute (approximately 50% of their normal breathing rate).
Study NCT03872843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norco 5milligram-325milligram Tablet
Description: Designated coated 7 days supply of pain medication (Norco 5 milligram-325milligram Tablet) will be sent home with discharged subjects. Pain medication is administered/scheduled 4 times per day until the stent will be removed in clinic a week later.
Study NCT03872843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 400 MILLIGRAM in 1 TABLET ORAL TABLET, FILM COATED
Description: Designated coated 7 days supply of pain medication (Ibuprofen 400 milligram) will be sent home with discharged subjects. Pain medication is administered/scheduled 4 times a day as needed until the stent will be removed in clinic a week later.
Study NCT04344652 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photoscreening -
Description: external picture taken with a an phone based app
Study NCT04097769 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: HX009
Description: During study treatment, subjects will receive HX009 treatment via IV infusion once every 2 weeks at doses of 0.1, 0.3, 1, 2, 3, 5, and 7.5 mg/kg.
Study NCT04964336 — intervention group
Intervention type: OTHER
Intervention: Analysis of B cells
Description: B cells from blood and cerebrospinal fluid will be analyzed using RNA-seq
Study NCT04469270 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engensis
Description: Intramuscular injections
Study NCT04469270 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injections
Study NCT04009499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab at pre-specified time-points.
Study NCT02824224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: 10mg PO (by mouth) twice daily for 7 days starting on day 21 after IUD insertion for one course
Study NCT02824224 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Tamoxifen)
Description: Sugar pill manufactured to mimic the tamoxifen 10mg tablet
Study NCT02403583 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intervention- Home Visits
Description: If a woman has been randomized to the intervention arm, a lay health worker will obtain detailed locator information (including cell phone contacts) and consult with the woman about optimal times for a home visit. The woman will be given a letter for her male partner to inform him about the study and potential upcoming visits, given that our preliminary research revealed that notifying the male partner beforehand is important. As described above, the intervention arm will consist of three home visits conducted by one female and one male lay health worker.
Study NCT01610856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol
Description: 4 Litres of polyethylene glycol bowel preparation solution
Study NCT01610856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol
Description: Polyethylene glycol 4L given in two split doses of 2L each
Study NCT04366154 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: delivery of questionnaires on perceived stress, post-traumatic stress, sleep disorders, quality of life, cognitive complaint
Study NCT00856999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: Botox Cosmetic will be delivered in standard doses of 4 units per injection site over a total of 5 sites, thus treating the procerus and corrugator superciliaris muscle groups
Study NCT02388828 — intervention group
Intervention type: BIOLOGICAL
Intervention: lentiviral-based CART meso therapy
Study NCT03350490 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cancer ablation
Description: Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
Study NCT03350490 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cancer ablation
Description: Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
Study NCT03350490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Life information rehabilitation therapy
Description: Each treatment: one bottle solution each day, consecutive 3 months, oral administration
Study NCT03350490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Life information rehabilitation therapy
Description: Each treatment: one bottle solution each day, consecutive 3 months, oral administration
Study NCT02104245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin dispersion for inhalation
Study NCT02104245 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02454348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressin
Description: Subjects will receive vasopressin (0.04 units/min) by continuous infusion to achieve and maintain a target mean arterial pressure (65-75 mm Hg). The treating physician may choose the initial dosage of norepinephrine within the initial range of 0.05-0.5 mcg/kg/min. The treating physician may alter the target mean arterial pressure if clinically indicated.
Study NCT02454348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Subjects will receive norepinephrine (0.05 to 0.5 mcg/kg/min) by continuous infusion with titration by bedside nurse to achieve and maintain a target mean arterial pressure (65-75 mm Hg). The treating physician may choose the initial dosage of norepinephrine within the initial range of 0.05-0.5 mcg/kg/min. The treating physician may alter the target mean arterial pressure if clinically indicated.
Study NCT04330417 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Hand Training
Description: Perform activities of daily living, e.g., write sentences, turn cards, move small and big objects, simulated feeding, stack checkers, pour water, squeeze handles
Study NCT04330417 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Hand Therapy
Description: Stretching, Strengthening, Hand Functional Training
Study NCT03413163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultrasound guided erector spinae plane block
Description: A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to T9 spinous process. The erector spinae muscles will be identified superficial to the tip of T9 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 17-gauge 8-cm needle will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of 0.375% bupivacaine will be injected (maximum of 3mg/kg).
Study NCT03413163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Pain Followup and Monitorization
Description: Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
Study NCT03413163 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard Pain Followup and Monitorization
Description: Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
Study NCT03446976 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P13 SC Auto-injector
Description: Each subject may receive single dose by subcutaneous administration using Auto-Injector
Study NCT03446976 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P13 SC Pre-filled Syringe
Description: Each subject may receive single dose by subcutaneous administration using Pre-filled Syringe
Study NCT03373760 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT03373760 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03373760 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study NCT01093586 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: double-unit umbilical cord blood transplantation
Description: Undergo transplantation
Study NCT01093586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cytogenetic analysis
Description: Correlative studies
Study NCT01093586 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow aspiration
Description: Correlative studies
Study NCT01093586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluorescence in situ hybridization
Description: Correlative studies
Study NCT01093586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given orally
Study NCT01093586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT01093586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: Given IV
Study NCT01093586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Given IV
Study NCT01093586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV
Study NCT01093586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given orally or IV
Study NCT01093586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies
Study NCT01093586 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo transplantation
Study NCT00105989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Study NCT00105989 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01773603 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Embryoscope
Description: Five-day embryo culture in embryoscope which is an incubator with a built-in camera
Study NCT00357877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10% w/v chlorhexidine acetate coating FDA IND #45466
Description: Dental coating topically applied by dental professional supragingivally to the full dentition
Study NCT00357877 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01051557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01051557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: Given PO
Study NCT01051557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study NCT01051557 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo cytoreductive surgery
Study NCT01863290 — intervention group
Intervention type: OTHER
Intervention: Primary care redesign
Description: Connect individuals released from prison to primary care using trained, culturally competent primary care providers and community health workers (CHWs).
Study NCT00534872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-649868
Description: 10 mg
Study NCT02950116 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Perform three multiple breath nitrogen washout tests (N2-MBW-test)
Description: * Patient is sitting in upright position, nose clip in place and breathing through a mouth piece with filter (neither sitting forward with back bent, nor supporting arms such that shoulders are raised)~* Patient's breathing pattern is stable for a minimum of 5 breaths~* Start of washout by inhaling 100% oxygen (initiated by lab technician)~* Continuous stable breathing pattern until end of washout test~* End target = 1/40th of start N2 concentration~* To ensure end of washout is achieved, patients should breathe 5 more breaths below the target concentration before the trial is terminated~* Three N2-MBW-tests are performed consecutively. Time between each test is \[duration of the previous test\*1.5\] (e.g. test duration = 6 min., time to next test = 6\*1.5 = 9 min.)
Study NCT02959216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Participants will be given a prescription to exercise up to 90% of their threshold heart rate for symptom exacerbation. Heart rate threshold will be monitored weekly in order to increase exercise level accordingly.
Study NCT02959216 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Stretching Exercise
Description: Participants will be given a prescription to complete a standardized stretching protocol.
Study NCT02988739 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: seasonal influenza vaccine
Description: influenza vaccine containing 15 µg haemagglutinin of three seasonal influenza virus strains recommended by WHO
Study NCT02988739 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: seasonal influenza vaccine
Description: influenza vaccine containing 15 µg haemagglutinin of three seasonal influenza virus strains recommended by WHO
Study NCT02988739 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fractional Er:Yag laser
Description: Fraction laser device to apply micorpores of defined depth and density into skin.
Study NCT01869777 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bioelectric impedance analysis
Description: Undergo bioelectric impedance analysis
Study NCT03866421 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MR spectroscopy of the liver
Description: Magnetic resonance spectroscopy of the liver. Golden standard for non-invasive determination of NAFLD
Study NCT03866421 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fibroscan of the liver
Description: Transient Elastography for Measurement of liver fibrosis.
Study NCT03866421 — intervention group
Intervention type: DEVICE
Intervention: Continuous glucose monitoring (CGM) for four days.
Description: CGM is attached to the abdominal skin for four days. Afterwards data is converted and analysed in a computer program.
Study NCT03866421 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Oral glucose tolerance test (OGTT)
Description: OGTT with incretin hormones. Measured for three hours.
Study NCT03866421 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Intra venous glucose infusion (IIGI)
Description: This test is combined with the OGTT to compare responses of parenteral vs enteral stimulation. The test is followed by a bolus of 5 g of L-arginin.